Infuvite Adult Vial 2

Drug overview for INFUVITE ADULT VIAL 2 (multivitamin infusion adult no.4,vit k,component vial 2 of 2):

Generic name: MULTIVITAMIN INFUSION ADULT NO.4,VIT K,COMPONENT VIAL 2 OF 2
Drug class: Multivitamins
Therapeutic class: Electrolyte Balance-Nutritional Products

Phytonadione is a fat-soluble naphthoquinone derivative that is identical to naturally occurring vitamin K1.

Numerous multivitamin preparations are marketed, with little standardization of formulas. Useful multivitamin preparations should contain only essential vitamins (those for which there is a recommended daily dietary allowance (RDA)). (See Dosage and Administration.) Preparations containing iron and/or calcium supplements may be useful in some patients (e.g., pregnant or lactating women) but other essential minerals are usually obtained from the diet.

The addition of agents such as liver, yeast, and wheat germ to vitamin preparations offers no advantage over pure chemical ingredients, and inclusion of nonessential agents such as choline, bioflavonoids, inositol, betaine, lecithin, and methionine is unwarranted. Combinations of vitamins and other drugs such as hormones are irrational and should not be used. Phytonadione is used in the prophylaxis and/or treatment of coagulation disorders due to faulty formation of factors II, VII, IX, and X caused by vitamin K deficiency or interference with vitamin K activity.

Phytonadione is more effective than, and is preferred to, other vitamin K preparations in the presence of impending or actual hemorrhage. However, because phytonadione may require 3 hours or longer to stop active bleeding, administration of clotting factors (e.g., prothrombin complex concentrate (human)), fresh whole blood, or plasma may be necessary for more rapid control of severe bleeding.

DRUG IMAGES

No Image Available

The following indications for INFUVITE ADULT VIAL 2 (multivitamin infusion adult no.4,vit k,component vial 2 of 2) have been approved by the FDA:

Indications:
Vitamin deficiency prevention
Vitamin deficiency

Professional Synonyms:
Vitamin deficiency prophylaxis

The following dosing information is available for INFUVITE ADULT VIAL 2 (multivitamin infusion adult no.4,vit k,component vial 2 of 2):

Dosing
Administration
Dosing Information
Generic

Dose, frequency of administration, and duration of treatment with phytonadione depend on the severity of the prothrombin deficiency and the response of the patient; the lowest effective dose of phytonadione should be used.

Vitamins are usually administered orally; however, the drugs may be given parenterally in patients in whom oral administration is not feasible, including those receiving total parenteral nutrition. For IV administration, vitamins should be diluted according to the manufacturers' recommendations. Multivitamin injections are reportedly incompatible with IV solutions containing various drugs.

Published data are too varied and/or limited to permit generalizations, and specialized references should be consulted for specific compatibility information. Phytonadione may be administered orally or parenterally (IV, IM, or subcutaneously). The parenteral preparation also has been administered orally+ in neonates.

The route of administration of phytonadione depends on the severity of the prothrombin deficiency and the risks associated with administration by each route. The manufacturers state that because of the possibility of severe adverse reactions (see Cautions: Adverse Effects), IV or IM administration is indicated only when other routes of administration are not feasible and the serious risk is justified. However, the effects of phytonadione have been reported to be delayed and/or unpredictable following subcutaneous injection, and subcutaneous administration may be less effective for reversal of excessive anticoagulation than IV or oral administration.

The American College of Chest Physicians (ACCP) and other clinicians recommend IV administration of phytonadione in emergency situations for major bleeding due to vitamin K-antagonist anticoagulants because of its more rapid onset; these clinicians recommend that subcutaneous administration be avoided. Oral administration of phytonadione usually reduces international normalized ratio (INR) levels in 24-48 hours and generally is recommended over parenteral administration in selected asymptomatic (nonbleeding) patients with hypoprothrombinemia due to vitamin K-antagonist anticoagulants. In patients with decreased bile secretion, bile salts (e.g., ox bile extract 300 mg or dehydrocholic acid 500 mg) should be given with each oral dose of phytonadione to ensure absorption.

Parenteral administration is indicated in patients who are unable to retain or absorb the drug from the GI tract. When phytonadione injection is administered IV, it should be injected at a rate not exceeding 1 mg/minute. The drug may be diluted for infusion with 0.9%

sodium chloride, 5% dextrose, or 5% dextrose in 0.9% sodium chloride injection; other diluents that may contain benzyl alcohol should not be used. (See Cautions: Pediatric Precautions.) The drug should be administered immediately after dilution, and any unused portion of the dilution and the unused contents of the ampul or vial should be discarded.

The infusion container must be protected from light at all times. (See Chemistry and Stability: Stability.)

No dosing information available.

No generic dosing information available.

The following drug interaction information is available for INFUVITE ADULT VIAL 2 (multivitamin infusion adult no.4,vit k,component vial 2 of 2):

Contraindicated
Severe
Moderate

There are 0 contraindications.

There are 0 severe interactions.

There are 1 moderate interactions. The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.

Drug Interaction	Drug Names
Pafolacianine/Folic Acid SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Folate, folic acid, and folate-containing supplements may reduce binding of pafolacianine to folate receptors expressed on ovarian cancer cells. CLINICAL EFFECTS: Folate, folic acid, and folate-containing supplements could reduce the detection of malignant lesions with pafolacianine. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid administration of folate, folic acid, or folate-containing supplements within 48 hours before administration of pafolacianine. DISCUSSION: Folate, folic acid, and folate-containing supplements may reduce binding of pafolacianine to folate receptors expressed on cancer cells, which could result in reduced detection of malignant lesions with pafolacianine.	CYTALUX

Drug Interaction

Drug Names

Pafolacianine/Folic Acid

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Folate, folic acid, and folate-containing supplements may reduce binding of pafolacianine to folate receptors expressed on ovarian cancer cells.

CLINICAL EFFECTS: Folate, folic acid, and folate-containing supplements could reduce the detection of malignant lesions with pafolacianine.

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Avoid administration of folate, folic acid, or folate-containing supplements within 48 hours before administration of pafolacianine.

DISCUSSION: Folate, folic acid, and folate-containing supplements may reduce binding of pafolacianine to folate receptors expressed on cancer cells, which could result in reduced detection of malignant lesions with pafolacianine.

CYTALUX

The following adverse reaction information is available for INFUVITE ADULT VIAL 2 (multivitamin infusion adult no.4,vit k,component vial 2 of 2):

Overview
Severe
Less Severe

Adverse reaction overview.

No enhanced Common Adverse Effects information available for this drug.

There are 2 severe adverse reactions.

More Frequent	Less Frequent
None.	None.

Rare/Very Rare
Bronchospastic pulmonary disease Concentration difficulty

There are 14 less severe adverse reactions.

More Frequent	Less Frequent
None.	None.

Rare/Very Rare
Abdominal distension Acute cognitive impairment Anorexia Depression Dysgeusia Erythema Excitement Flatulence Irritability Malaise Nausea Pruritus of skin Skin rash Sleep disorder

The following precautions are available for INFUVITE ADULT VIAL 2 (multivitamin infusion adult no.4,vit k,component vial 2 of 2):

Pediatric
Pregnant
Lactation
Geriatric

No enhanced Pediatric Use information available for this drug.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

Reproduction studies have not been conducted in animals, and it is not known if phytonadione has teratogenic effects.

No enhanced Lactation information available for this drug.

No enhanced Geriatric Use information available for this drug.

Vitamin deficiency
E56.9	Vitamin deficiency, unspecified